Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
Neuro-Oncology|June 19, 2023
Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastomaLena Hänsch, Matthias Peipp, Maximilian Mastall, et al.
Protein Science : a Publication of the Protein Society|February 13, 2023
NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formatsBritta Lipinski, Paul Arras, Lukas Pekar, et al.
Frontiers in Immunology|January 31, 2020
Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivoAnja Schaffert, Maja Hanić, Mislav Novokmet, et al.
Cancer Research|April 19, 2005
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7Edwin Bremer, Douwe F Samplonius, Matthias Peipp, et al.
Marine Drugs|July 25, 2015
Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer CellsUlf Geisen, Marion Zenthoefer, Matthias Peipp, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 27, 2017
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated CytotoxicityTim Wirt, Sophia Rosskopf, Thies Rösner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2012
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicityChristian Kellner, Tina Maurer, Daniela Hallack, et al.
Mabs|February 5, 2014
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibodyChristina Brunke, Stefan Lohse, Stefanie Derer, et al.
British Journal of Haematology|April 3, 2004
A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cellsJoerg Bruenke, Barbara Fischer, Karin Barbin, et al.
Blood|July 10, 2010
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignanciesHolly M Horton, Matthew J Bernett, Matthias Peipp, et al.
Pageof 13